HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) Removed old template contents |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Indolent T-cell lymphoma of the gastrointestinal tract}} | {{DISPLAYTITLE:Indolent T-cell lymphoma of the gastrointestinal tract}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 37: | Line 38: | ||
|} | |} | ||
==WHO Essential and Desirable Genetic Diagnostic Criteria== | ==WHO Essential and Desirable Genetic Diagnostic Criteria== | ||
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | <span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | ||
| Line 231: | Line 126: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
| Line 244: | Line 139: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0">{{Cite journal|last=A|first=Sharma|last2=N|first2=Oishi|last3=Rl|first3=Boddicker|last4=G|first4=Hu|last5=Hk|first5=Benson|last6=Rp|first6=Ketterling|last7=Pt|first7=Greipp|last8=Dl|first8=Knutson|last9=Sm|first9=Kloft-Nelson|date=2018|title=Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/29592893/|language=en|doi=10.1182/blood-2018-01-830968|pmc=PMC5958657|pmid=29592893}}</ref><blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | <center><span style="color:Maroon">'''End of V4 Section'''</span> | ||
---- | ---- | ||
| Line 254: | Line 149: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
| Line 292: | Line 187: | ||
|NKp46 | |NKp46 | ||
|Possible role in diagnosis (exclusion) | |Possible role in diagnosis (exclusion) | ||
|Positive stain does not favor the diagnosis<ref name=":3" /> but seen in type 2 refractory celiac disease, EATL and MEITL | |Positive stain does not favor the diagnosis<ref name=":3">{{Cite journal|last=M|first=Cheminant|last2=J|first2=Bruneau|last3=G|first3=Malamut|last4=D|first4=Sibon|last5=N|first5=Guegan|last6=T|first6=van Gils|last7=S|first7=Cording|last8=A|first8=Trinquand|last9=V|first9=Verkarre|date=2019|title=NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study|url=https://pubmed.ncbi.nlm.nih.gov/30448772/|language=en|pmid=30448772}}</ref> but seen in type 2 refractory celiac disease, EATL and MEITL | ||
|} | |} | ||
*'''Prognosis'''<ref name=":2" /> | *'''Prognosis'''<ref name=":2">{{Cite journal|last=Am|first=Perry|last2=Ra|first2=Warnke|last3=Q|first3=Hu|last4=P|first4=Gaulard|last5=C|first5=Copie-Bergman|last6=S|first6=Alkan|last7=Hy|first7=Wang|last8=Jx|first8=Cheng|last9=Cm|first9=Bacon|date=2013|title=Indolent T-cell lymphoproliferative disease of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/24009234/|language=en|doi=10.1182/blood-2013-07-512830|pmc=PMC3837508|pmid=24009234}}</ref> | ||
**Indolent, but chronic relapsing clinical course | **Indolent, but chronic relapsing clinical course | ||
*'''Therapeutic Implications''' | *'''Therapeutic Implications''' | ||
**Generally unresponsive to therapy<ref name=":1" /> | **Generally unresponsive to therapy<ref name=":1">{{Cite journal|last=E|first=Margolskee|last2=V|first2=Jobanputra|last3=Sk|first3=Lewis|last4=B|first4=Alobeid|last5=Ph|first5=Green|last6=G|first6=Bhagat|date=2013|title=Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features|url=https://pubmed.ncbi.nlm.nih.gov/23861889/|language=en|doi=10.1371/journal.pone.0068343|pmc=PMC3701677|pmid=23861889}}</ref> | ||
***The potential use of JAK-STAT inhibitors such as tofacinib and AZD1480 has not been formally tested | ***The potential use of JAK-STAT inhibitors such as tofacinib and AZD1480 has not been formally tested | ||
| Line 362: | Line 257: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 412: | Line 307: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1" /><blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | <center><span style="color:Maroon">'''End of V4 Section'''</span> | ||
---- | ---- | ||
| Line 458: | Line 353: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* | * | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 514: | Line 409: | ||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
| Line 526: | Line 421: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Cr|first=Soderquist|last2=N|first2=Patel|last3=Vv|first3=Murty|last4=S|first4=Betman|last5=N|first5=Aggarwal|last6=Kh|first6=Young|last7=L|first7=Xerri|last8=R|first8=Leeman-Neill|last9=Sk|first9=Lewis|date=2020|title=Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract|url=https://pubmed.ncbi.nlm.nih.gov/31558678/|language=en|doi=10.3324/haematol.2019.230961|pmc=PMC7327650|pmid=31558678}}</ref><blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | <center><span style="color:Maroon">'''End of V4 Section'''</span> | ||
---- | ---- | ||
| Line 563: | Line 458: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
| Line 569: | Line 464: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0" /><blockquote class="blockedit"> | ||
<center><span style="color:Maroon">'''End of V4 Section'''</span> | <center><span style="color:Maroon">'''End of V4 Section'''</span> | ||
---- | ---- | ||
| Line 601: | Line 496: | ||
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | ||
<br /> | |||
==Notes== | ==Notes== | ||
| Line 610: | Line 505: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Indolent T-cell lymphoma of the gastrointestinal tract”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Indolent_T-cell_lymphoma_of_the_gastrointestinal_tract</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “Indolent T-cell lymphoma of the gastrointestinal tract”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Indolent_T-cell_lymphoma_of_the_gastrointestinal_tract</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases I]] | |||